Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + epacadostat
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Pembrolizumab + epacadostat is a combination therapy investigated for the treatment of advanced or metastatic solid tumors, including melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma, endometrial adenocarcinoma, urothelial carcinoma, and squamous cell carcinoma of the head and neck. Pembrolizumab is a monoclonal antibody that targets the programmed cell death protein 1 receptor (PD-1) on T cells, blocking its interaction with PD-L1 and PD-L2 to enhance anti-tumor immune responses. Epacadostat is an orally administered small molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1), an enzyme involved in tryptophan metabolism that suppresses immune responses in the tumor microenvironment. By inhibiting IDO1, epacadostat aims to restore effector T cell function and synergize with checkpoint inhibition by pembrolizumab. The combination has shown antitumor activity in early-phase clinical trials but failed to demonstrate benefit over monotherapy in a large phase III trial for advanced melanoma[1][2][3][4][6].
- Brand names
- Keytruda
- Other names
- pembrolizumab + epacadostat
02
Targets
IDO1 (Indoleamine 2,3-dioxygenase 1)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on pembrolizumab + epacadostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + epacadostat.